Difference between revisions of "WSI22-127-Case-2"

From MGH Learn Pathology
Line 44: Line 44:
 
|subject=Z0FBQUFBQmpJNXVCX01xR0JjbGNySTdUbHRUbTF5clk4bEd4Qnp4NEtVZnQtSzhIdlhGZ3haWkt1SHUzOTJCRGo1S1lkdE1MMzQ5RC1lV1hOSGRRQXc1Ung0QXI2ejZ6Vmc9PQ
 
|subject=Z0FBQUFBQmpJNXVCX01xR0JjbGNySTdUbHRUbTF5clk4bEd4Qnp4NEtVZnQtSzhIdlhGZ3haWkt1SHUzOTJCRGo1S1lkdE1MMzQ5RC1lV1hOSGRRQXc1Ung0QXI2ejZ6Vmc9PQ
 
|reasonCode=H&E
 
|reasonCode=H&E
|view=hide
+
|view=show
 
|modality=mrxs
 
|modality=mrxs
 
}}
 
}}

Revision as of 10:51, September 16, 2022

WSI22-127-Case-2
30s female with thyroid mass and enlarged bilateral lymph nodes.
Papillary thyroid carcinoma, diffuse sclerosing variant. Follow-up molecular: CCDC6(e1)::RET(e12) fusion.
October 26, 2022 1:15:00 AM